Semaglutide vs Survodutide
FDA Approved vs Extensively Studied
avoid Mechanism-based · 70% Both Semaglutide and Survodutide activate GLP-1 receptors. Combining GLP-1 agonists significantly increases risk of severe GI side effects (nausea, vomiting, pancreatitis). Not recommended.
Molecular Data
Semaglutide Survodutide
Weight 4,113.64 Da ~4,500 Da
Half-life ~7 days (168 hours) Approximately 6 days (109-115 hours)
Chain 31 amino acids 29 amino acids
Type GLP-1 receptor agonist Peptide with fatty acid acylation
Key Benefits
Semaglutide
01 15-20% average body weight reduction
02 Established cardiovascular protection
03 Convenient once-weekly dosing options
04 Comprehensive safety data from extensive trials
05 Flexible injectable and oral formulations
Survodutide
01 Superior weight loss vs monotherapy (14.9% at 46 weeks)
02 Once-weekly convenient dosing
03 Proven efficacy in obesity, MASH, and Type 2 diabetes
04 62% MASH improvement in clinical trials
Dosing Protocols
Semaglutide
0.25mg starting, titrate to 1-2.4mg weekly / Once weekly (same day each week)
Weight Loss Initiation 0.25mg Weekly x 4 weeks, then increase
Weight Loss Maintenance 2.4mg Weekly (after 16-week titration)
Diabetes Management 0.5-1mg Weekly
Cardiovascular Protection 0.5-1mg Weekly
Tolerability-Based 0.25-2.4mg Weekly (individualized)
Survodutide
0.6mg starting, titrate up to 3.6-6.0mg weekly / Once weekly (same day each week)
Obesity - Conservative Start 0.6mg titrated over 24 weeks Once weekly with 4-week intervals
Obesity - Standard Protocol 3.6-6.0mg Once weekly
MASH Treatment 2.4-4.8mg Once weekly
Type 2 Diabetes 0.3-2.7mg Once weekly
Side Effects
Semaglutide
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Survodutide
Nausea (40-66%)
Diarrhea (25-49%)
Vomiting (15-41%)
Slight heart rate increase (mean 2-5 bpm)
Contraindications
Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy or breastfeeding
History of pancreatitis
Not recommended in pregnancy or breastfeeding
Use contraception during treatment
Research Evidence
Semaglutide Survodutide
Status FDA Approved Extensively Studied
References 9 studies 3 studies
Latest 2025-06 —
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.